close Video

NEW You can now listen to Fox News articles!

An experimental drug has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).

BCG (Bacillus Calmette-Guérin) is an immunotherapy drug that is often the first-line treatment for certain early-stage bladder cancers.

The new drug, TAR-200 — which was evaluated in a trial sponsored and conducted by Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson — may offer a less invasive alternative to bladder removal surgery .

KILLER CONDITION LANDS IN TOP 10 LEADING CAUSES OF DEATH AS GLOBAL CASES SURGE

TAR-200 is a small, drug-releasing device placed directly into the bladder through a simple outpatient procedure, without

See Full Page